Objective: In ageing men, the incidence and clinical significance of testosterone (T) decline accompanied by elevated luteinising hormone (LH) are unclear. We describe the natural history, risk factors and clinical features associated with the development of biochemical primary hypogonadism (PHG, T<10.5nmol/L and LH>9.4U/L) in ageing men.
Introduction
Low circulating testosterone (T) concentration is common in ageing men, increasing in prevalence from 20% to 50% between 60-80 years of age 1 , but only a very small proportion develops symptomatic hypogonadism. In the European Male Ageing Study (EMAS) of 40-79
year-old community-dwelling men, the prevalence of low T (<10.5nmol/L) was 13.8% 2 , but hypogonadism (defined by low T with 3 cognate symptoms) could be identified in only 2.1% 3 . Others have also found a significantly lower prevalence of symptomatic hypogonadism compared to that of biochemical hypogonadism (low T) 4 
. Conspicuously, low
T and putative hypogonadal symptoms are seldom detected in the same men, highlighting
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their tenuous association and the substantial overlap between features of hypogonadism and those of ageing and chronic illness 2, 4 . Utilising changes in the tightly regulated feedback relationships in the hypothalamic-pituitary-testicular (HPT) axis, by combining gonadotrophin with T measurements, may enhance the precision of detecting, or predicting the advent, of unequivocal androgen deficiency in ageing men.
Biochemical hypogonadism can be divided into primary hypogonadism (PHG, elevated gonadotrophin level, testicular defect) and secondary hypogonadism (SHG, low or inappropriately normal gonadotrophin level, hypothalamic-pituitary defect) 2 . Cross-sectional analyses of EMAS baseline data found PHG to be strongly associated with higher age, but not obesity, while SHG was predominantly found in connection with obesity, and was independent of age 2, 5 . In the present study, we report, for the first time, prospective observational data regarding the predisposing factors and clinical features of men who developed PHG.
Methods

Participants and study design
The study design (including the assessments described below in "Other measures") and recruitment strategy for EMAS have been described previously 6, 7 . Briefly, an age-stratified sample of 3,369 men aged 40-79 (mean ±SD: 60 ±11) years was recruited from population registers in eight European centres. Participants were assessed on two occasions separated by a median of 4.3 (range 3.0-5.7) years. Ethical approval for the study was obtained in accordance with local requirements in each centre. All participants provided written informed
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Hormone measurements
A single fasting morning (before 1000) blood sample was obtained at baseline and follow-up. T was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 8 , with paired baseline and follow-up samples analysed simultaneously. LH, FSH and SHBG were measured by the E170 platform electrochemiluminescence immunoassay (Roche Diagnostics). The Vermeulen formula was used to calculate free (f) T 9 . Intra-and inter-assay coefficients of variation (CV) were: T 4.0 and 5.6%; LH 1.9 and 2.7%; FSH 0.9% and 1.9%; and SHBG 1.9 and 3.2%. Insulin was assayed using chemiluminescence (CVs: 3.9% and 5%). Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR) 10 .
Biochemistry/haematology
Standardised measurements were undertaken in laboratories in each centre.
Other measures
Participants answered questions about: smoking, alcohol consumption frequency and specific illness. A participant was considered to have a chronic illness if he had one (or more) of the following self-reported illnesses: heart problems, stroke, hypertension, diabetes, bronchitis, 
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Body weight and height were measured by electronic scale and stadiometer (SECA UK).
Physical function was assessed by Reuben's Physical Performance Test (PPT) and cognitive processing speed by Wechsler's Digit-Symbol Substitution test (DSST).
Gonadal status
Participants were assigned gonadal status according to total T and LH levels. Current guidelines recommend use of total T rather than free T to define hypogonadism 11, 12 . Men with a T≥10.5 nmol/L were considered eugonadal (EUG) and men with a T<10.5 nmol/L and a LH>9.4 U/L were considered to have primary hypogonadism (PHG) 2 . Subjects were categorised further by their change in gonadal status into one of four groups: (1) persistent (p) EUG -EUG at baseline and at follow-up; (2) incident (i) PHG -EUG at baseline and PHG at follow-up; (3) persistent pPHG -PHG at both baseline and follow-up; and (4) reversed (r) PHG -reversal of PHG at baseline to EUG at follow-up.
Statistical analysis
Baseline and follow-up characteristics were compared between groups using Mann-Whitney U or Kruskal-Wallis analyses for continuous variables and Chi squared tests for categorical variables. Post-hoc analyses were performed using Tukey-Kramer tests with correction for multiple pairwise comparisons. Multiple regression models were used to assess associations of clinical variables with iPHG, or pPHG, using pEUG as the referent group. In assessing potential risk factors for PHG, centre was included in the regression model as a randomeffects variable and the potential risk factors as fixed-effects variables 2 
. Multiple regression
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Results from linear regression models are presented as regression coefficients (for standardised variables) with 95% confidence intervals (CI) and from logistic regression models as odds ratios (OR) with CI. All statistical analyses were conducted using STATA version 13 (StataCorp, College Station, TX).
Results
Gonadal status transition
Of the 3,369 men that participated in EMAS, 1,991 men made up the main analytical sample after exclusion of those with known pituitary, testicular or adrenal disease (n=94), failure to attend for follow-up assessment (n=575), missing T or LH data (n=122), and SHG (n=369, Figure 1 ). Those currently using steroid hormones (n=11 at baseline, n=17 at follow-up), gonadotrophin-releasing hormone analogues (n=9 at baseline, n=3 at follow-up), antiandrogens (n=45 at baseline, n=31 at follow-up), 5-alpha reductase inhibitors (n=38 at baseline, n=46 at follow-up) and strong opioids (n=13 at baseline, n=4 at follow-up) were excluded also. Compared to the main analytical sample, men lost to follow-up (n=407) were older, had higher BMI, higher smoking prevalence, higher HOMA-IR, worse physical and cognitive function and had more illnesses (Supplemental Table 1 ). This was the case also for men who died (n=168) with the exception of no difference, compared to the main analytical sample, in BMI or HOMA-IR.
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Amongst the 1,991 men in the analytical sample, 1,942 (97.5%) had pEUG and 22 (1.1%) developed PHG giving an annual incidence (95% confidence interval) of 0.24%/year (0.10-0.58) assuming linearity of PHG development. The prevalence of PHG at follow-up was 2.1% (n=49). Taking into account the baseline prevalence of PHG of 1.7% (n=54), the cumulative prevalence rate of PHG was therefore 3.1% amongst the EMAS cohort.
Of 54 men who had PHG at baseline, 18 (33.3%) were lost to follow-up, had medical exclusions or no follow-up hormone data. Of the remainder, 7 died (19.4%). Of the remaining men with PHG at baseline who had follow-up data (n=29), 22 (75.9%) continued to have PHG at follow-up, 5 (17.2%) reverted to EUG at follow-up and 2 (6.9%) developed SHG.
Cohort Characteristics
At baseline, age was higher, triglyceride to HDL-cholesterol ratio was higher and SF36 physical function score was lower in iPHG compared with pEUG men (Table 1 ). In addition, iPHG men had lower cognitive function (DSST). At follow-up, the differences in age, SF36 physical function score and DSST between the groups persisted, while iPHG men also had lower haemoglobin, a lower mean physical function rating (PPT, an objective measure of physical function). The prevalence of 2 or more illnesses and cardiovascular disease in the iPHG group was greater than that in the pEUG group at baseline and at follow-up. Erectile dysfunction was more prevalent in the iPHG group than in pEUG at follow-up, as was walking limitation and decreased vigour. Men with pPHG differed significantly from those with pEUG in the same parameters (as iPHG) except for the triglyceride to HDL-cholesterol ratio at baseline. In addition, men with pPHG had higher BMI and HOMA-IR and lower physical activity (PASE) and baseline haemoglobin compared to men with pEUG. Like men
Accepted Article
with iPHG, those with pPHG had more illnesses and more sexual and physical symptoms than pEUG men.
Hormone levels
Baseline total T in iPHG (13.2 ±2.3 nmol/L) was significantly lower than in pEUG (18.4 ±5.4 nmol/L, p<0.05, Figure 2 ). Total T decreased during follow-up to 9.3 ±0.9 nmol/L in iPHG men and to 18.1 ±5.4 nmol/L in pEUG men with a greater decline evident for iPHG men (mean changes -3.9 ±2.7 nmol/L and -0.3 ±4.1 nmol/L, p<0.05). Total T decreased also in pPHG men (from 7.3 ±2.4 nmol/L to 5.9 ±2.9 nmol/L) and, by definition, rose in rPHG men 
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Symptoms and functional ratings associated with PHG
At baseline, men who developed PHG during follow-up (iPHG) had lower sexual thought frequency, increased erectile dysfunction, decreased vigour ( Figure 4A ), lower haemoglobin, lower physical function, higher depression score and lower cognitive function than men who remained eugonadal (pEUG, Figure 4B ). However, only erectile dysfunction and haemoglobin changed (worsened) more during follow-up in iPHG men than in pEUG men.
At follow-up, the prevalences of erectile dysfunction and decreased vigour were greater in the iPHG group than in the pEUG group. At follow-up also, men with iPHG had lower haemoglobin, lower physical function, higher depression score and lower cognitive function than men with pEUG.
After adjustment for age and chronic illness, the only parameters that remained significantly associated with iPHG ( Figure 4 , open symbols) were SF36 physical function score at baseline, fall in haemoglobin during follow-up and erectile dysfunction, decreased vigour and lower haemoglobin at follow-up. However, the power of these adjusted comparisons is limited by the small number of iPHG men due to the low incidence.
Among pPHG men (PHG at baseline and at follow-up), all three sexual symptoms were more prevalent at baseline and follow-up in comparison to pEUG men ( Figure 5A ). Frequency of sexual thoughts decreased and erectile dysfunction worsened more in the pPHG. Decreased vigour was more prevalent, at baseline and follow-up. Low mood was more prevalent in pPHG than in pEUG men at baseline only. Haemoglobin levels were significantly lower, and HOMA-IR values significantly higher, in pPHG at baseline and follow-up than in pEUG
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( Figure 5B ). SF-36 Physical Function score, PPT rating and DSST were similarly reduced at baseline and follow-up in pPHG, but only PPT rating worsened more.
After adjustment for age and chronic illness, decreased morning erections, haemoglobin and increased HOMA-IR at baseline and decreased sexual thoughts, haemoglobin and HOMA-IR at follow-up remained significantly associated with pPHG ( Figure 5 , open symbols). Again, the power of these adjusted comparisons is limited by the small number of pPHG men.
Discussion
We describe the natural history of, the predisposing factors for and the clinical features associated with biochemically-defined primary hypogonadism in the general population.
Age-related biochemical PHG is a relatively uncommon entity predominantly affecting men over the age of 70 years with multiple illnesses who bear little resemblance to the burgeoning population of patients actively seeking testosterone replacement 13 .
Natural history of PHG
The relative rarity of biochemical PHG in the EMAS population was indicated by a baseline prevalence of 1.7% and confirmed at follow-up by a prevalence 2.1%, giving an incidence of only 0.2%/year. In contrast, SHG is much more common having a baseline prevalence of 11.5%, and an 8-fold higher incidence of 1.6%/y 2, 14 . These figures cannot be directly compared with previously reported incidence of symptomatic hypogonadism of 10% over 9 years 15 and prevalence estimates of >20% for overall hypogonadism in the ageing male population 1, 4, 16 , since these earlier studies did not make the differentiation between PHG and SHG. These prevalence rates were determined after exclusion of men with disease of the
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Ageing-related PHG appears to be mostly irreversible; T levels returned to normal in only 4.3%/year. This contrasts with SHG which, in EMAS, had a rate of reversal of 9.7%/year 14 .
Of the original 54 men with PHG at baseline, 7 (13.0%) died during the follow-up period, which is 2.5-fold higher than in the whole study population. Hence, the state of PHG may beckon a serious deterioration in health. This is compatible with our, and others', previous finding that late-onset hypogonadism is associated with substantially increased mortality 17, 18 .
Risk factors for PHG
Advanced age and multiple chronic illnesses are the factors that most strongly predicted the development of iPHG. In this respect PHG differs substantially from the more common SHG -obesity predicted SHG, but age and chronic illness did not 14 . These important and consistent differences in the risk factors and natural history between PHG and SHG offer useful insights and guidance for clinical decision making in symptomatic older men presenting with low T.
There is a large body of evidence showing that T levels decrease with ageing in men, ranging in various longitudinal studies from 0.04 to 2.6% per year after the age of 40 1, 16, [19] [20] [21] .
However, obesity strongly influences the magnitude of decline in T independent of age 21 .
There are also data suggesting that T levels can be maintained in highly selected elderly men who remain in good health 22 , making the case that it is not age per se, but ageing-related health deterioration that affects T production. The HPT axis is tightly regulated in men 5 and LH levels are highly responsive to any deficits in Leydig cell function 23 . Impaired testicular
Accepted Article
This article is protected by copyright. All rights reserved. response to LH can be caused by exposure to pro-inflammatory cytokines 24-26 , arising from chronic low grade inflammation 27 , associated with ageing and chronic illness 26 . It is well known that chronic illnesses associated with inflammation, such as cancer and obesity, are associated with multi-level disruption of the HPT axis 28 . Many younger men with chronic illness have, therefore, low T with non-elevated LH level (SHG) due to such multi-level disruption. Our finding that chronic illness is a risk factor for PHG, but not SHG 14 is consistent with recent data showing an independent association between elevated LH with cardiovascular disease 29 and decreased muscle strength 30 . One can surmise, therefore, that excessive elevation of LH (over and above that associated with ageing per se and independent of T) can be regarded as a barometer of poor health in ageing men 31 .
Endocrinology of PHG
PHG is characterised by elevation of gonadotrophins that is unable to counteract impaired ±2.1 nmol/L) in the iPHG group but LH showed little concurrent change (from 16.5 ±14.0 to 18.5 ±11.5 U/L). This suggests that the HPT axis had reached the limit of its compensating capacity possibly due to a superimposing element of hypothalamic dysfunction 23 , thereby allowing testicular failure to supervene. Development of PHG can therefore be predicted
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Clinical characteristics of PHG
The development of biochemical PHG was associated with the development (or worsening) of erectile dysfunction, decreased vigour and lower haemoglobin. Many of the observed differences (from pEUG) in clinical characteristics were already apparent at baseline in those EUG men destined to develop PHG during follow-up. Although only a selection of these features remained statistically significant after adjustment for age and health status, there appears to be a trend of increasing symptoms and functional deficits across iPHG to pPHG (Figures 4 and 5) . This trend is concurrent with the progressive decline in T and the duration of hypogonadism, although our observational data cannot ascribe causality to these associations. Interestingly, these findings tally well with those of the recently published There are a number of potential explanations for the relatively limited number of statistically significant associations between the development of biochemical PHG with putative 'hypogonadal' features and functional deficits. The PHG group comprised older men (mean age over 65) in whom deteriorating health from chronic diseases gives rise to a multitude of symptoms and functional deficits, which overlap with those of androgen deficiency. The picture of presumed androgen deficiency in men developing PHG is therefore confounded by a background of non-specific features of senescence. The small number of men with iPHG and pPHG does not provide adequate statistical power to detect small differences (signals)
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against the significant prevalence of background (noise) symptoms and deficits (unrelated to T levels). In iPHG men, LH was already higher, and their T significantly lower, at baseline, than in pEUG men. It can therefore be argued that the iPHG men were already borderline 'hypogonadal', i.e. they had compensated hypogonadism with relatively lower mean total T and in particular free T. This may have introduced biases against differentiating the characteristics of iPHG from pEUG. Notwithstanding these issues, the finding of associations between iPHG and pPHG with sexual symptoms, decreased vigour, physical function and haemoglobin suggest that biochemical PHG may identify a small group of men with clinical features compatible androgen deficiency. The main limitation in this analysis is the relatively small number of men developing PHG during follow-up -this is unavoidable given the relative rarity of the condition which has not been previously described. This may have restricted the power of our analyses to clearly differentiate changes that could have been related to androgen deficiency from those due to age-related health deterioration. Even with the small number of cases, however, some
Strengths and weaknesses
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clinically useful insight has been captured. Other limitations in EMAS have been described previously 6, 7 . The mortality-adjusted retention rate of 86.2% may have introduced an unmeasured survivor bias, but this potential censoring of men with lower T or higher LH 
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